The vaccine is known as BNT162b1 and is being developed in conjunction with BioNTech SE
The results are based on the first 45 people enrolled in the clinical trial since late April
The company said those who received the vaccine produced more antibodies than someone who had recovered from a coronavirus infection
Preliminary results from a clinical trial of the BNT162b1 messenger RNA vaccine indicate the vaccine triggers a significant immune response in recipients, Pfizer (PFE) and BioNTech SE (BNTX) announced Wednesday.
The vaccine is among 150 currently under evaluation worldwide. Though there is no guarantee a safe and effective vaccine ever will be developed, several candidates have been labeled promising.
“We are encouraged by the clinical data of BNT162b1, one of four mRNA constructs we are evaluating clinically, and for which we have positive, preliminary, topline findings,” Pfizer Senior Vice President and head of Vaccine Research and Development Kathrin U. Jansen said in a press release.
The phase 1/2 U.S. clinical trial began enrolling 7,600 participants at the end of April. The first batch of 45 subjects were broken into three groups: 24 individuals who received the vaccine in two doses, 21 days apart; 12 subjects who received a single, higher dose of the vaccine, and a third group that was given a placebo.
Those who received the vaccine, whether one dose or two, had more antibodies in their blood after 21 days than people who had recovered from coronavirus infections, the companies said.
Adverse reactions included a low-grade fever, primarily after the second dose, and pain at the injection site.
A global phase 2b/3 safety and efficacy trial was expected to begin later this month and involve as many as 30,000 healthy participants.